Age-adjusted Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiation therapy

作者：Tanaka Hidenori; Takenaka Yukinori^*; Nakahara Susumu; Hanamoto Atshushi; Fukusumi Takahito; Michiba Takahiro; Takemoto Norihiko; Cho Hironori; Yamamoto Masashi; Yamamoto Yoshifumi; Inohara Hidenori

来源：Acta Oto-Laryngologica, 2017, 137(6): 668-673.

DOI：10.1080/00016489.2016.1269946

• Hypopharynx
• squamous cell cancer
• head and neck
• radiation
• chemotherapy

Conclusion: The age-adjusted Charlson comorbidity index (ACCI) was associated with overall survival, disease-specific survival, and non-cancer death in patients treated with chemoradiation therapy (CRT) for hypopharyngeal cancer (HPC). Further studies using other CRT regimens are required.Objective: To investigate the impact of the ACCI on survival in patients with HPC.Methods: This study reviewed 128 patients with HPC who received CRT between 2004-2012. The survival rates and the cumulative incidence of non-cancer death according to the ACCI were estimated. A Cox proportional hazard model was used to assess the hazard ratio (HR) of the ACCI.Results: The disease-specific survival rates at 3 years for the low ACCI group, moderate group, and high group were 80.1%, 45.8%, and 54.8%, respectively (p=0.007). The laryngectomy-free survival rates at 3 years were 61%, 39.7%, and 37.1%, respectively (p=0.137). The cumulative incidences of non-HPC death were 5% for the low/moderate ACCI group and 15.5% for the high ACCI group (p=0.031). The HRs compared to the low ACCI group for overall survival, disease-specific survival, and laryngectomy-free survival were 2.61 and 2.74, 2.55 and 2.27, and 1.75 and 1.97 in the moderate and high ACCI groups, respectively.

• 出版日期2017-6